Some key tumor progression-associated genes like PTEN in astrocytoma and in embryonal tumors, MYCN in ependymoma, and BRCA2 in glioneuronal/neuronal tumors would not otherwise have been identified as significantly differentially expressed in the tumors had the cell type proportions not been adjusted for. The gene discussed is BRCA2; the disease is astrocytoma (excluding glioblastoma).